Important Update
Obeticholic acid (Ocaliva) has recently been licenced in Canada for the treatment of people with PBC who have not fully responded to, or who are unable to tolerate, Ursodeoxycholic acid.
Early trials show reduction in liver fibrosis
The American Association for the Study of Liver Diseases published findings that the ASK1 Inhibitor Selonsertib reduced liver fibrosis in stage 2-3 liver fibrosis. In late 2016 Gilead announced that First patients in Canada now taking Ocaliva
After waiting 20 years, this month PBC patients have started on their new treatment option, Ocaliva. For patients who do not respond to ursodeoxycholic acid this has been tremendous news.
New PBC treatment for Itch now in clinical trials in Canada
Itch is common in people with PBC. Currently available treatments are not always effective and may have side effects. In PBC, the bile ducts in the liver become damaged which
Positive Interim Results for Phase 2 PBC Drug Trial
CymaBay announced positive interim results from its ongoing low-dose Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC), a life-threatening and life-limiting chronic cholestatic liver disease. In First new PBC treatment in 20 years approved!
The Canadian PBC Society is excited to share that a new treatment option for PBC is on it’s way, thanks to the recent Canadian approval of Ocaliva , otherwise known
"Liver Dialysis" Trial Begins in the UK/EU
“Liver dialysis” trial begins in the UK/EU with 24 patients at 7 sites – adding 100 EU patients in 2018.The aim is to remove toxins that accumulate in liver failure
Another PBC Drug going into Phase 2 Trial
“Genkyotex Initiates Patient Enrollment into Phase 2 Trial of GKT831 in Primary Biliary Cholangitis” – Read More
New PBC Drug First Patients enrolled in Phase 2 Trial
“GENFIT: First Patient enrolled in a Phase 2 Trial recruiting Adults with Primary Biliary Cholangitis (PBC), a Rare Liver Disease ” – Read More